| Assessment Status | Rapid Review Complete |
| HTA ID | 23051 |
| Drug | Fenfluramine |
| Brand | Fintepla® |
| Indication | Fenfluramine (Fintepla®) is indicated for patients (two years of age and older) with Lennox-Gastaut Syndrome as an add-on therapy to other anti-epileptic medicines. |
| Assessment Process | |
| Rapid review commissioned | 09/08/2023 |
| Rapid review completed | 14/09/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine for this indication compared with the current standard of care. |
